JP2010053122A5 - - Google Patents

Download PDF

Info

Publication number
JP2010053122A5
JP2010053122A5 JP2009173561A JP2009173561A JP2010053122A5 JP 2010053122 A5 JP2010053122 A5 JP 2010053122A5 JP 2009173561 A JP2009173561 A JP 2009173561A JP 2009173561 A JP2009173561 A JP 2009173561A JP 2010053122 A5 JP2010053122 A5 JP 2010053122A5
Authority
JP
Japan
Prior art keywords
synthesis
inhibitor
fatty acid
involved
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009173561A
Other languages
Japanese (ja)
Other versions
JP2010053122A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2009173561A priority Critical patent/JP2010053122A/en
Priority claimed from JP2009173561A external-priority patent/JP2010053122A/en
Publication of JP2010053122A publication Critical patent/JP2010053122A/en
Publication of JP2010053122A5 publication Critical patent/JP2010053122A5/ja
Withdrawn legal-status Critical Current

Links

Claims (4)

有効成分としてプロポリス抽出物を含有し、さらに、デキストリン、プルラン、環状四糖、ラクトスクロース、糖転移ビタミンP類、糖転移ビタミンC及びコタラヒム抽出物から選ばれる何れか1種又は2種以上を配合した脂質合成阻害剤。 Contains propolis extract as an active ingredient , and further contains one or more selected from dextrin, pullulan, cyclic tetrasaccharide, lactosucrose, glycosylated vitamin Ps, glycosylated vitamin C and Kotarahim extract lipid synthesis inhibitor that is. トリグリセリド合成阻害剤及び/又はコレステロール合成阻害剤である請求項1記載の脂質合成阻害剤。 The lipid synthesis inhibitor according to claim 1 , which is a triglyceride synthesis inhibitor and / or a cholesterol synthesis inhibitor. トリグリセリド合成に関与する遺伝子発現阻害剤及び/又はコレステロール合成に関与する遺伝子発現阻害剤である請求項1又は2記載の脂質合成阻害剤。 The lipid synthesis inhibitor according to claim 1 or 2, which is a gene expression inhibitor involved in triglyceride synthesis and / or a gene expression inhibitor involved in cholesterol synthesis. トリグリセリド合成に関与する遺伝子が、脂肪酸合成転写因子1(Sterol regulatory element binding protein 1:SREBF1)、アセチルCoAカルボキシラーゼ(Acetyl CoA carboxylase:ACAC)及び/又は脂肪酸合成酵素(Fatty acid synthase:FAS)であり、コレステロール合成に関与する遺伝子が脂肪酸合成転写因子2(Sterol regulatory element binding protein 2:SREBF2)である請求項3記載の脂質合成阻害剤。 Genes involved in triglyceride synthesis are fatty acid synthesis transcription factor 1 (SREBF1), acetyl CoA carboxylase (Acetyl CoA carboxylase: ACAC) and / or fatty acid synthase (Fatty acid synthase: The lipid synthesis inhibitor according to claim 3, wherein the gene involved in cholesterol synthesis is fatty acid synthesis transcription factor 2 (SREBF2).
JP2009173561A 2008-07-31 2009-07-24 Lipid synthesis inhibitor Withdrawn JP2010053122A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009173561A JP2010053122A (en) 2008-07-31 2009-07-24 Lipid synthesis inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008198726 2008-07-31
JP2009173561A JP2010053122A (en) 2008-07-31 2009-07-24 Lipid synthesis inhibitor

Publications (2)

Publication Number Publication Date
JP2010053122A JP2010053122A (en) 2010-03-11
JP2010053122A5 true JP2010053122A5 (en) 2012-08-30

Family

ID=42069403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009173561A Withdrawn JP2010053122A (en) 2008-07-31 2009-07-24 Lipid synthesis inhibitor

Country Status (1)

Country Link
JP (1) JP2010053122A (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012095746A2 (en) 2011-01-11 2012-07-19 Capsugel Belgium Nv New hard capsules
JP5785500B2 (en) * 2012-01-11 2015-09-30 株式会社ヤクルト本社 Paffia extract-containing beverage
CN104189393A (en) * 2014-09-07 2014-12-10 王旭东 Traditional Chinese medicine preparation for treating stroke and preparation method thereof
CN104940747A (en) * 2015-06-08 2015-09-30 柳州市宝杨种植专业合作社 Novel traditional Chinese medicine formula for preventing and treating cardiovascular and cerebrovascular diseases
BR112019021391A2 (en) 2017-04-14 2020-05-05 Capsugel Belgium Nv pullulan capsules
US11319566B2 (en) 2017-04-14 2022-05-03 Capsugel Belgium Nv Process for making pullulan
JP2022036341A (en) * 2018-10-12 2022-03-08 学校法人慶應義塾 Pharmaceutical composition for treating chronic dermatitis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100540559C (en) * 2003-04-03 2009-09-16 株式会社林原生物化学研究所 Lipid-regulating agent and uses thereof
JP2009057283A (en) * 2005-12-21 2009-03-19 Konan Kako Kk Angiopathy ameliorating agent comprising sulfated polysaccharide derived from green alga, and method for producing the same

Similar Documents

Publication Publication Date Title
JP2010053122A5 (en)
WO2017059223A3 (en) Compositions and methods for inhibiting gene expression of lpa
CL2004000626A1 (en) COMPOUNDS DERIVED FROM BENCENOSULFONAMIDE, ITS SALTS; PHARMACEUTICAL COMPOSITION, AND ITS USE IN THE TREATMENT OF A DISEASE RELATED TO CCR3, SUCH AS ASTHMA, ATOPIC DERMATITIS, RHINITIS, HIV, PULMONARY GRANULOMA, ALZHEIMER.
WO2008131419A3 (en) Glycoconjugates of rna interference agents
WO2007120811A3 (en) Hemangio-colony forming cells
WO2007107162A3 (en) Small internally segmented interfering rna
WO2012119078A3 (en) COMPOSITIONS AND METHODS COMPRISING C16:1n7-PALMITOLEATE
BRPI1103910A8 (en) PRODUCTION OF ISOMALTOOLIGOSACCHARIDES AND THEIR USES
EP2011544A3 (en) Structured Depilatory Compositions
JP2011136976A5 (en)
JP2013119547A5 (en)
AR080123A1 (en) COMPOSITIONS AND METHODS FOR THE INHIBITION OF THE EXPRESSION OF THE GENES OF QUINASE 2-KAPPA B (IKK2)
TH47306S1 (en) Refractory brick support structures
TH118538S (en) Refractory brick support structures
TH118506S (en) Crucible Support Stand
TH99553S (en) chair
TH40489S1 (en) chair
TH37352S1 (en) Shelf
TH37354S1 (en) Shelf
TH111868S (en) Shelf
TH136663B (en) Recombinant yeast and a method for producing matter using the same
TH40124S1 (en) Partition joints
TH34164S1 (en) Watch case
TH101868S (en) Watch case
TH106236S (en) CD rack